Company: SCLXW
Filing Date: 2025-08-04
Form Type: S-1
Source: 0001193125-25-172703
Chunk: 29

Company: Scilex Holding Co
Filing Date: 2025-08-04
Form: S-1
Chunk 29
---
 outstanding before this Offering(1) . | 6,955,697 shares of Common Stock |

| Shares of Common Stock outstanding after the Offering | 8,346,140 shares of Common Stock |

| Terms of the Offering | The Selling Stockholder will determine when and how it will dispose of any shares of Common Stock registered under this prospectus for resale. However, we may receive up to $100,000,000 in aggregate gross proceeds under the Tumim Purchase Agreement from sales of Common Stock that we may elect to make to the Selling Stockholder pursuant to the Tumim Purchase Agreement, if any, from time to time in our discretion. We expect to use the net proceeds that we receive under the Tumim Purchase Agreement for working capital and general corporate purposes, which may include capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. However, we have not designated any specific uses and have no current agreement with respect to any acquisition or strategic transaction. See “Use of Proceeds.” |

| Use of proceeds | We will not receive any proceeds from the sale of shares of Common Stock by the Selling Stockholder. See “Use of Proceeds” elsewhere in this prospectus. |

| Market for our Common Stock | Our Common Stock is listed on the Nasdaq Capital Market under the symbol “SCLX”. |

| Risk factors | See “Risk Factors” beginning on page 27 and other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in the securities being offered by this prospectus. |

| (1) | The number of shares of Common Stock outstanding assumes that an aggregate of 6,955,697 shares are outstanding as of July 31, 2025, and excludes: |

| • |     | 18,657 shares of Common Stock issuable upon the exercise of stock options outstanding under the 2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan (the “Scilex Pharma 2017 Plan”) with a weighted average exercise price of $27.03 per share; |

| • |     | 431,287 shares of Common Stock issuable upon the exercise of stock options outstanding under the 2019 Stock Option Plan of Scilex, Inc. (the “2019 Stock Option Plan”) with a weighted average exercise price of $60.55 per share